The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A CostUtility Analysis
Abstract
BACKGROUND: Once-in-a-lifetime screening for Barrett esophagus has been proposed for patients with gastroesophageal reflux disease (GERD), but there is little evidence of its cost-effectiveness. OBJECTIVE: 1) To determine the cost-effectiveness of screening high-risk groups for Barrett esophagus and providing surveillance to patients with Barrett esophagus and dysplasia or to all patients with Barrett esophagus and 2) to compare the results with the cost-effectiveness of no screening or surveillance. DESIGN: A decision analytic model was developed to examine no screening or surveillance and screening and surveillance for Barrett esophagus with dysplasia only or Barrett esophagus without dysplasia every 2 to 5 years. Low- or high-grade dysplasia received surveillance every 6 or 3 months, respectively. DATA SOURCES: Published literature and the Health Care Financing Administration. TARGET POPULATION: 50-year-old white men with symptoms of GERD. TIME HORIZON: 50 years of age until 80 years of age or death. PERSPECTIVE: Third-party payer. OUTCOME MEASURE: Incremental cost-effectiveness ratio. RESULTS OF BASE-CASE ANALYSIS: Screening with surveillance limited to patients with Barrett esophagus with dysplasia required $10 440 per quality-adjusted life-year (QALY) saved compared to no screening or surveillance. The incremental cost-effectiveness ratio of surveillance every 5 years in patients with Barrett esophagus without dysplasia compared to surveillance of patients with Barrett esophagus with dysplasia was $596 000 per QALY saved. RESULTS OF SENSITIVITY ANALYSIS: The annual incidence of adenocarcinoma must exceed 1 case per 54 patient-years of follow-up (1.9%) for surveillance of Barrett esophagus without dysplasia every 5 years to yield an incremental cost-effectiveness ratio less than $50 000 per QALY saved. CONCLUSIONS: Screening 50-year-old men with symptoms of GERD to detect adenocarcinoma associated with Barrett esophagus is probably cost-effective. However, subsequent surveillance of patients with Barrett esophagus but no dysplasia, even at 5-year intervals, is an expensive practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma
Lagergren, J., Bergström, R., Lindgren, A., & Nyrén, O. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401101 · Cited by 3,020
Self-citationRecommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Markov Models in Medical Decision Making: A Practical Guide
Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419
Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus
Wang, K. K., & Sampliner, R. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01835.x · Cited by 2,014
Self-citationThe Role of Cost-effectiveness Analysis in Health and Medicine
Russell, L. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140060028 · Cited by 1,167
Recommendations for Reporting Cost-effectiveness Analyses
Siegel, J. E. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540160061034 · Cited by 1,147
Siegel, J. E. (1996) · JAMA · doi:10.1001/jama.276.16.1339 · Cited by 1,037
The Markov process in medical prognosis
Beck, J. R., & Pauker, S. G. (1983) · Medical Decision Making · doi:10.1177/0272989x8300300403 · Cited by 957 · cited 1×
“A Markov model was used to analyze patients with symptomatic GERD (15, 16).”
MethodSpechler, S. J., Lee, E., Ahnen, D., Goyal, R. K., Hirano, I., Ramirez, F., Raufman, J.-P., Sampliner, R., Schnell, T., Sontag, S., et al. (2001) · JAMA · doi:10.1001/jama.285.18.2331 · Cited by 909
Self-citationOesophageal squamous cell carcinoma: I. A critical review of surgery
Earlam, R., & Cunha-Melo, J. R. (1980) · Journal of British Surgery · doi:10.1002/bjs.1800670602 · Cited by 902
Cited by
ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus
Shaheen, N. J., Falk, G. W., Iyer, P. G., & Gerson, L. B. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.322 · Cited by 1,501
Incidence of Adenocarcinoma among Patients with Barrett's Esophagus
Hvid-Jensen, F., Pedersen, L., Drewes, A. M., Sørensen, H. T., & Funch-Jensen, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103042 · Cited by 1,371
Fitzgerald, R. C., di Pietro, M., Ragunath, K., Ang, Y., Kang, J.-Y., Watson, P., Trudgill, N., Patel, P., Kaye, P. V., Sanders, S., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305372 · Cited by 1,346
Self-citationAmerican Gastroenterological Association Technical Review on the Management of Barrett's Esophagus
Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M., & Shaheen, N. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.031 · Cited by 1,060
Self-citationSharma, P., Dent, J., Armstrong, D., Bergman, J. J. G. H. M., Gossner, L., Hoshihara, Y., Jankowski, J. A., Junghard, O., Lundell, L., Tytgat, G. N. J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.032 · Cited by 1,049
Metadata
- Authors
- Inadomi, J. M., Sampliner, R., Lagergren, J., Lieberman, D., Fendrick, A. M., & Vakil, N.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2003-02-04
- Volume
- 138
- Issue
- 3
- Pages
- 176-186
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1982997453
- Cited by
- 361
- References
- 39
- FWCI
- 31.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A CostUtility Analysis. https://app.cochat.ai/papers/10.7326/0003-4819-138-3-200302040-00009
- The paper
- Inadomi, J. M., Sampliner, R., Lagergren, J., Lieberman, D., Fendrick, A. M., & Vakil, N. (2003). Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A CostUtility Analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-138-3-200302040-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.